Boulder, Colo.-based Array Biopharma Inc. will be receiving a $5 million milestone payment following the announcement that Astrazeneca plc has begun a Phase III trial for selumetinib, an oral MEK inhibitor, being investigated as second-line therapy in patients with metastatic non-small-cell lung cancer (NSCLC) whose tumors are KRAS mutation-positive.